Operating Expenses
Acquired IPR&D Expense
Neurocrine Biosciences Acquired IPR&D Expense increased by 24.7% to $21.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 21100.0%, from $100.00K to $21.20M. Over 4 years (FY 2021 to FY 2025), Acquired IPR&D Expense shows a downward trend with a -36.2% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
First reportedQ1 2017
Last reportedQ1 2026May 5, 2026
Metric ID:
abbv_acquired_iprd_expenseHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.00M | $0.00 | $100.30M | $0.00 | $0.00 | $0.00 | $0.00 | $143.90M | $0.00 | $0.00 | $0.00 | $6.00M | $2.50M | $1.00M | $3.00M | $100.00K | $0.00 | $300.00K | $17.00M | $21.20M |
| QoQ Change | — | -100.0% | — | -100.0% | — | — | — | — | -100.0% | — | — | — | -58.3% | -60.0% | +200.0% | -96.7% | -100.0% | — | >999% | +24.7% |
| YoY Change | — | — | — | — | -100.0% | — | -100.0% | — | — | — | — | -95.8% | — | — | — | -98.3% | -100.0% | -70.0% | +466.7% | >999% |
Range$0.00 – $143.90M
CAGR+35.5%
Avg YoY Growth>999%
Median YoY Growth-97.1%
Current Streak2 quarters growth
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $100.00K | $0.00 | $300.00K | $17.00M | $21.20M |
| Total | $100.00K | $0.00 | $300.00K | $17.00M | $21.20M |
Acquired IPR&D Expense at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's acquired ipr&d expense?
- Neurocrine Biosciences (NBIX) reported acquired ipr&d expense of $21.20M in Q1 2026.
- How has Neurocrine Biosciences's acquired ipr&d expense changed year-over-year?
- Neurocrine Biosciences's acquired ipr&d expense increased by 21100.0% year-over-year, from $100.00K to $21.20M.
- What is the long-term trend for Neurocrine Biosciences's acquired ipr&d expense?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's acquired ipr&d expense has grown at a -36.2% compound annual growth rate (CAGR), from $105.30M to $17.40M.